Brief: Adagene Establishes Collaboration For Clinical Trial Of ADG106 In Combination With Nivolumab
27/10/2021 13:11
Oct 27 (Reuters) - Adagene Inc 978y.F :
* ADAGENE ESTABLISHES COLLABORATION FOR CLINICAL TRIAL OF
ADG106
IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH NON-SMALL CELL
LUNG CANCER IN SINGAPORE
* ADAGENE INC - ADG106 NOW BEING EVALUATED IN COMBINATIONS
WITH
THREE LEADING ANTI-PD-1 THERAPIES
Source text for Eikon: ID:nGNX2Cp1Rk
Further company coverage: 978y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate
Brief: Adagene Inc - Partners With Conjugatebio For Antibody Drug Conjugate Development
Brief: Adagene Announces Up To $25 Million Strategic Investment From Sanofi